Thanks. I think the barrier to starting a biotech company is higher as you can't bootstrap as easily (though it is becoming easier to do so) and you can't get e

Thanks. I think the barrier to starting a biotech company is higher as you can't bootstrap as easily (though it is becoming easier to do so) and you can't get exponential growth on a tiny amount of capital (which you can do in tech with product market fit) The exit environment has been good lately. The M&A market will be strong for the foreseeable future bc big pharma relies on startups for new drugs when existing drugs go off patent. The IPO market has been good, but that could change for a number of reasons, including rising interest rates